Stopping Antidepressants in Pregnancy Raises Relapse Risk

By Health Desk | February 2026

Discontinuing antidepressant medication during pregnancy may significantly increase the risk of relapse in women with a history of major depressive disorder, mental health experts warn. Several large-scale cohort studies suggest that abruptly stopping prescribed antidepressants can nearly double the likelihood of depressive recurrence during pregnancy.

While concerns about fetal safety often prompt medication discontinuation, psychiatrists emphasize that untreated maternal depression carries its own serious health risks — both for the mother and the developing baby.

The debate highlights the delicate balance between medication safety and mental health stability during pregnancy.

What Research Says About Relapse Risk

Multiple longitudinal studies have examined outcomes among pregnant women who either continued or discontinued antidepressant treatment.

A frequently cited prospective cohort study published in a leading psychiatric journal found that women who discontinued antidepressants during pregnancy experienced relapse rates nearly twice as high as those who maintained treatment.

Researchers observed that:

Women who stopped medication were significantly more likely to experience depressive recurrence
Relapse often occurred during the first or second trimester
Women with recurrent depression histories were particularly vulnerable

Another large population-based study in Europe reported similar findings, indicating increased psychiatric hospital visits among women who discontinued treatment compared to those who continued under supervision.

Mental health experts emphasize that depression during pregnancy is more common than many assume. Research estimates indicate that nearly 10–20% of pregnant women experience clinically significant depressive symptoms at some point during pregnancy. This highlights the importance of early screening, timely psychological support, and structured perinatal mental health care to protect both maternal wellbeing and fetal development.

Why Relapse Risk Increases

Psychiatrists explain that pregnancy involves substantial hormonal, psychological, and lifestyle changes.

Estrogen and progesterone levels fluctuate dramatically, influencing neurotransmitters such as serotonin — the primary target of many antidepressant medications.

When antidepressants are abruptly stopped:

Brain chemistry may destabilize
Withdrawal symptoms may occur
Pre-existing depressive pathways may reactivate

For women with a history of recurrent major depression, stopping medication without medical supervision can create a biological vulnerability during an already sensitive period.

Experts caution that relapse during pregnancy is not just an emotional setback — it can have broader health consequences.

Risks of Untreated Depression During Pregnancy

While medication exposure raises concerns, untreated maternal depression is associated with documented medical risks.

Research has linked untreated depression in pregnancy to:

Poor prenatal care adherence
Increased risk of preterm birth
Low birth weight
Higher stress hormone levels
Sleep disturbances
Nutritional deficiencies

Severe untreated depression may also increase the risk of suicidal thoughts or self-harm behaviors.

According to data from the World Health Organization, maternal mental health conditions are a significant contributor to pregnancy-related morbidity globally.

Mental health specialists emphasize that risk assessment must consider both medication exposure and untreated psychiatric illness.

Medication Safety: What Studies Indicate

Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed antidepressants during pregnancy.

Large observational studies suggest that while certain medications may carry small risks, most commonly prescribed SSRIs are not associated with major congenital malformations when used appropriately.

However, researchers also note:

Some studies report a slight increase in neonatal adaptation syndrome (temporary withdrawal-like symptoms in newborns)
Rare associations with persistent pulmonary hypertension have been investigated
Absolute risk levels remain low

Experts stress that risk must be interpreted in context. For many women with moderate to severe depression, continuing treatment under medical supervision may present lower overall risk than discontinuation.

Individualized Risk Assessment Is Key

Obstetricians and psychiatrists consistently emphasize that decisions about antidepressant use during pregnancy should never be made abruptly or without medical consultation.

Clinical guidelines generally recommend:

Evaluating depression severity
Reviewing psychiatric history
Assessing relapse risk
Considering non-pharmacological therapies
Monitoring closely throughout pregnancy

For women with mild depression and strong support systems, supervised tapering may be appropriate.

However, for women with recurrent or severe depressive episodes, experts often advise continuation with close monitoring.

Abrupt discontinuation without medical guidance is strongly discouraged.

Psychological Stress of Medication Decisions

Pregnancy often intensifies anxiety around medication safety.

Women may experience:

Guilt over potential fetal exposure
Fear of harming the baby
Pressure from family members
Conflicting online information

Mental health professionals say this stress itself can worsen depressive symptoms.

Evidence suggests that clear counseling from healthcare providers reduces anxiety and improves treatment adherence.

Non-Medication Therapies: Are They Enough?

Psychotherapy, particularly cognitive behavioral therapy (CBT) and interpersonal therapy (IPT), has demonstrated effectiveness for mild to moderate depression.

Lifestyle interventions such as:

Regular sleep routines
Nutritional optimization
Social support engagement
Prenatal yoga or mindfulness practices

may also contribute to emotional stability.

However, experts caution that psychotherapy alone may not be sufficient for individuals with severe or recurrent major depressive disorder.

A combined treatment approach is often recommended.

Postpartum Depression Considerations

Another critical concern is postpartum relapse.

Studies show that women who experience depression during pregnancy are at increased risk of postpartum depression.

Discontinuing antidepressants during pregnancy may increase vulnerability in the postpartum period — a time already marked by hormonal shifts, sleep deprivation, and adjustment stress.

Early mental health planning during pregnancy can significantly reduce postpartum complications.

What Experts Recommend

Mental health experts generally advise:

Never stopping antidepressants abruptly without medical supervision
Consulting both an obstetrician and psychiatrist
Discussing risk-benefit analysis in detail
Monitoring mood symptoms regularly
Involving partners or family in emotional support planning

Shared decision-making models — where patients and doctors collaboratively evaluate options — are increasingly recommended.

Ongoing Research and Clinical Debate

Medical research continues to evolve regarding antidepressant safety in pregnancy.

While some older studies raised concerns, more recent large-scale analyses suggest that many risks are smaller than previously feared.

Experts emphasize the importance of:

Updated evidence review
Avoiding misinformation
Distinguishing between correlation and causation
Recognizing untreated depression as a serious medical condition

The conversation is shifting from “medication versus no medication” to “which treatment plan offers the lowest overall risk.”

A Balanced Perspective

Stopping antidepressants during pregnancy is not a simple decision. Research indicates that for many women with a history of significant depression, discontinuation may nearly double relapse risk.

At the same time, medication safety requires careful evaluation.

Experts stress that pregnancy mental health should be treated with the same seriousness as physical health.

The goal is not universal continuation or universal discontinuation — but individualized, medically supervised care.

Recognizing Warning Signals During Pregnancy

Pregnancy naturally brings emotional shifts — but clinical depression does not quietly blend into normal hormonal change. The difference often lies in intensity, duration, and impact on functioning.

Mental health professionals explain that concern arises when emotional distress:

Persists beyond two consecutive weeks
Begins affecting sleep, nutrition, or prenatal care routines
Interferes with work or household responsibilities
Creates emotional detachment from the pregnancy
Leads to persistent fear, guilt, or hopeless thinking

Unlike temporary mood swings, antenatal depression tends to feel heavy, repetitive, and difficult to regulate without support.

Experts emphasize that women who are considering stopping antidepressants — or who have already discontinued them — should be particularly attentive to:

Sudden mood crashes
Heightened irritability or anxiety spikes
Crying episodes without clear triggers
Loss of motivation to attend medical appointments

These patterns are not simply “pregnancy hormones.” They can signal relapse.

Clinical consultation at this stage is preventive, not reactive. Early discussion allows doctors to review medication safety profiles, explore dosage adjustments, consider therapy support, and monitor maternal–fetal wellbeing more closely.

Pregnancy care is not only physical — emotional stability is equally part of prenatal health.